PO‐322 exerts potent immunosuppressive effects in vitro and in vivo by selectively inhibiting SGK1 activity

Citations Over Time

Abstract

PO-322 exerted immunosuppressive activity in vitro and in vivo by selectively inhibiting SGK1 activity. PO-322 represents a potential lead compound for the design and development of new drugs for the treatment of autoimmune diseases.

Related Papers

• → New perspective in immunotherapy: local imiquimod treatment(2010)7 cited
• → Melanoma Arising after Imiquimod Use(2014)6 cited
• → Topical Imiquimod(2009)1 cited
• Innovative uses of imiquimod.(2005)
• → Imiquimod Cream for BCC Treatment(2000)